BioVentureVoiCes

BioVenture VoiCes is a new video podcast on @BiotechTVHQ that will feature leading VC investors to discuss heathcare venture investing from an insider's perspective to dig deeper into best practices, strategies, and emerging trends and shifting landscape of healthcare technology!

Listen to Episode 40 of @BioVentureVoiCe video podcast w/ Krishna Yeshwant, Managing Partner at @GVteam and hear his journey from computer science to entrepreneurship and medicine to a founding team member at Google Ventures. The full video is here on @BiotechTV (and also on

Our next guest (Ep.40) on @BioVentureVoiCe video podcast will be Krishna Yeshwant @kyeshwant of GV/ Google Ventures @GVteam (gv.com) where he has led life science investing for over 15 years since their inception. He discusses how pursuing his degree in Computer

Listen to Episode 39 of @BioVentureVoiCe video podcast w/ Kate Bingham, Managing Partner and co-head of the biotech franchise for SV Health (svhealthinvestors.com), as she covers her 35 years at SV Health leading investments, the Dementia Discovery Fund, and her involvement in

Listen to Episode 38 of @BioVentureVoiCe video podcast w/ Jason Fuller, Partner at Deerfield Management (deerfield.com) where he has led therapeutics investments since 2021 after applying learnings from his career at NEA, Third Rock, company creation and leadership at

Our next guest (Ep.38) on @BioVentureVoiCe video podcast will be Jason Fuller of Deerfield Management (deerfield.com) who has over 15 years of experience at top VC firms leading investments for @ThirdRockV and @NEA, as well as company creation with Jounce Tx, before

RT @cngarabedian: Listen to Episode 37 of @BioVentureVoiCe video podcast w/ Simeon George, CEO and Managing Partner of SR One (https://t.co…

Our next guest (Ep.37) on @BioVentureVoiCe video podcast will be Simeon George of SR One (srone.com), formerly known as GSK's CVC arm, where he has been leading investments for almost 20 years and orchestrated its spinout as an independent investment firm in 2020 as

RT @cngarabedian: Listen to Episode 36 of @BioVentureVoiCe video podcast w/ Jim Healy, Chairman and Managing Partner of Sofinnova Investmen…

Our next guest (Ep.36) on @BioVentureVoiCe video podcast will be Jim Healy of Sofinnova Investments (sofinnova.com), where he has been leading biotech investments for over 25 years and joined the firm soon after completing his MD/PhD at Stanford. Sofinnova has embraced

Our next guest (Ep.35) on @BioVentureVoiCe video podcast will be Jessica Owens of INITIATE Ventures (initate.vc), a venture studio and early-stage VC she co-founded after her experience as a VC and serial entrepreneur at Kleiner Perkins, Versant and as co-founder and

RT @cngarabedian: Listen to Episode 34 of @BioVentureVoiCe video podcast w/ Brett Zbar of @generalatlantic and hear how his strategy in lea…

Our next guest (Ep.34) on @BioVentureVoiCe video podcast will be Brett Zbar of @generalatlantic, one of the larger PE firms, where he leads their life science investment practice. He joined General Atlantic after roles at McKinsey, Aisling and Foresite after his early experience

Listen to Episode 33 of @BioVentureVoiCe video podcast w/ Art Pappas of @pappas_capital and hear how 30 years of VC investing since the founding of the firm was born out of his pharma career building international operations and his relationships with industry partners in

Our next guest (Ep.33) on @BioVentureVoiCe video podcast will be Art Pappas of @pappas_capital, where he has been leading VC investments in life sciences for over 30 years. He shares how his 20+ career working in pharma leading international operations led to the founding of the firm and collaborative relationships that are still a pillar of the firm today. Tune in early next week to listen to this episode of BioVenture VoiCes on @BiotechTV !

@cngarabedian @rtnarch Apple Podcasts link: podcasts.apple.com/us/podcast/bio…

🔥Early release for #JPM26 🔥: Listen to Episode 32 of @BioVentureVoiCe video podcast w/ Bob Nelsen (@rtnarch) and hear about how Arch leans into risk-taking on great science in developing first-in-class technologies and platforms over their 40 year history. In the last 5 years (the most challeging market in biotech history), Arch has raised more money ($8B) and deployed more capital than any biotech VC and the firm doesn't have 'risk-averse' in their vocabulary. The full video is here on @BiotechTV (and also on Spotify and Apple Podcasts): biotechtv.com/post/bioventur…

@cngarabedian @rtnarch Spotify link: open.spotify.com/episode/57qgh2…

Our next guest (Ep.32) on @BioVentureVoiCe video podcast will be Bob Nelson (@rtnarch) of Arch Venture Partners. Bob describes his early influences and the founding of Arch 40 years ago and how the firm has been risk-tolerant and being first on new technology areas from its

Listen to Episode 31 of @BioVentureVoiCe video podcast w/ Amy Schulman of @PolarisVC and hear about her early career as a lawyer led to her General Counsel and Business Unit Executive at Pfizer before becoming a VC at Polaris, where she has led life science investments for over

Our next guest (Ep.31) on @BioVentureVoiCe video podcast will be Amy Schulman of @PolarisVC (polarispartners.com), where she has been leading biotech investments for over a decade. She shares her prior experience as GC and business leader for @pfizer along with her law firm